aluates Reports

$ 0.0

Automative

Global Drugs for Central Nervous System Diseases Market Insights, Forecast to 2030

Published Date: December 2024

Report Code: QYRE-Auto-16L3363

Global Drugs for Central Nervous System Diseases Market Insights Forecast to 2028

BUY CHAPTERS

Global Drugs for Central Nervous System Diseases Market Insights, Forecast to 2030

Code: QYRE-Auto-16L3363

Report

December 2024

Pages:109

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Alkermes plc

Astrazeneca plc

Biogen

Bristol–Myers Squibb

Lilly

GSK

Merck

Sunovion Pharmaceuticals

Pfizer Inc

TEVA

Norvatis

Drugs for Central Nervous System Diseases Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Drugs for Central Nervous System Diseases Market

A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous system

Market Analysis and Insights: Global Drugs for Central Nervous System Diseases Market

The global Drugs for Central Nervous System Diseases market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Covers:

This report presents an overview of global market for Drugs for Central Nervous System Diseases market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Drugs for Central Nervous System Diseases, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Drugs for Central Nervous System Diseases, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Central Nervous System Diseases revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Drugs for Central Nervous System Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Drugs for Central Nervous System Diseases revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Drugs for Central Nervous System Diseases Market Report

Report Metric	Details
Report Name	Drugs for Central Nervous System Diseases Market
CAGR	5%
Segment by Type	Antidepressants Anxiolytics Anti-manic Other
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Alkermes, Astrazeneca, Biogen, Bristol Myers Squibb, Lilly, GSK, Merck, Sunovion Pharmaceuticals, Pfizer, Teva, Norvatis
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Drugs for Central Nervous System Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Central Nervous System Diseases companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Central Nervous System Diseases revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the Drugs for Central Nervous System Diseases Market report?

Ans: The main players in the Drugs for Central Nervous System Diseases Market are Alkermes, Astrazeneca, Biogen, Bristol Myers Squibb, Lilly, GSK, Merck, Sunovion Pharmaceuticals, Pfizer, Teva, Norvatis

What are the Application segmentation covered in the Drugs for Central Nervous System Diseases Market report?

Ans: The Applications covered in the Drugs for Central Nervous System Diseases Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Drugs for Central Nervous System Diseases Market report?

Ans: The Types covered in the Drugs for Central Nervous System Diseases Market report are Antidepressants, Anxiolytics, Anti-manic, Other

Recommended Reports

Neurodegenerative Diseases

Depression & Anxiety

Nervous System Drugs

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Antidepressants

1.2.3 Anxiolytics

1.2.4 Anti-manic

1.2.5 Other

1.3 Market by Application

1.3.1 Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Drugs for Central Nervous System Diseases Market Perspective (2019-2030)

2.2 Global Drugs for Central Nervous System Diseases Growth Trends by Region

2.2.1 Drugs for Central Nervous System Diseases Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Drugs for Central Nervous System Diseases Historic Market Size by Region (2019-2024)

2.2.3 Drugs for Central Nervous System Diseases Forecasted Market Size by Region (2025-2030)

2.3 Drugs for Central Nervous System Diseases Market Dynamics

2.3.1 Drugs for Central Nervous System Diseases Industry Trends

2.3.2 Drugs for Central Nervous System Diseases Market Drivers

2.3.3 Drugs for Central Nervous System Diseases Market Challenges

2.3.4 Drugs for Central Nervous System Diseases Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Drugs for Central Nervous System Diseases by Players

3.1.1 Global Drugs for Central Nervous System Diseases Revenue by Players (2019-2024)

3.1.2 Global Drugs for Central Nervous System Diseases Revenue Market Share by Players (2019-2024)

3.2 Global Drugs for Central Nervous System Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Drugs for Central Nervous System Diseases, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Drugs for Central Nervous System Diseases Market Concentration Ratio

3.4.1 Global Drugs for Central Nervous System Diseases Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Drugs for Central Nervous System Diseases Revenue in 2023

3.5 Global Key Players of Drugs for Central Nervous System Diseases Head office and Area Served

3.6 Global Key Players of Drugs for Central Nervous System Diseases, Product and Application

3.7 Global Key Players of Drugs for Central Nervous System Diseases, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Drugs for Central Nervous System Diseases Breakdown Data by Type

4.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Type (2019-2024)

4.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2025-2030)

5 Drugs for Central Nervous System Diseases Breakdown Data by Application

5.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Application (2019-2024)

5.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Drugs for Central Nervous System Diseases Market Size (2019-2030)

6.2 North America Drugs for Central Nervous System Diseases Market Size by Type

6.2.1 North America Drugs for Central Nervous System Diseases Market Size by Type (2019-2024)

6.2.2 North America Drugs for Central Nervous System Diseases Market Size by Type (2025-2030)

6.2.3 North America Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

6.3 North America Drugs for Central Nervous System Diseases Market Size by Application

6.3.1 North America Drugs for Central Nervous System Diseases Market Size by Application (2019-2024)

6.3.2 North America Drugs for Central Nervous System Diseases Market Size by Application (2025-2030)

6.3.3 North America Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

6.4 North America Drugs for Central Nervous System Diseases Market Size by Country

6.4.1 North America Drugs for Central Nervous System Diseases Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Drugs for Central Nervous System Diseases Market Size by Country (2019-2024)

6.4.3 North America Drugs for Central Nervous System Diseases Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Drugs for Central Nervous System Diseases Market Size (2019-2030)

7.2 Europe Drugs for Central Nervous System Diseases Market Size by Type

7.2.1 Europe Drugs for Central Nervous System Diseases Market Size by Type (2019-2024)

7.2.2 Europe Drugs for Central Nervous System Diseases Market Size by Type (2025-2030)

7.2.3 Europe Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

7.3 Europe Drugs for Central Nervous System Diseases Market Size by Application

7.3.1 Europe Drugs for Central Nervous System Diseases Market Size by Application (2019-2024)

7.3.2 Europe Drugs for Central Nervous System Diseases Market Size by Application (2025-2030)

7.3.3 Europe Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

7.4 Europe Drugs for Central Nervous System Diseases Market Size by Country

7.4.1 Europe Drugs for Central Nervous System Diseases Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Drugs for Central Nervous System Diseases Market Size by Country (2019-2024)

7.4.3 Europe Drugs for Central Nervous System Diseases Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Drugs for Central Nervous System Diseases Market Size (2019-2030)

8.2 China Drugs for Central Nervous System Diseases Market Size by Type

8.2.1 China Drugs for Central Nervous System Diseases Market Size by Type (2019-2024)

8.2.2 China Drugs for Central Nervous System Diseases Market Size by Type (2025-2030)

8.2.3 China Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

8.3 China Drugs for Central Nervous System Diseases Market Size by Application

8.3.1 China Drugs for Central Nervous System Diseases Market Size by Application (2019-2024)

8.3.2 China Drugs for Central Nervous System Diseases Market Size by Application (2025-2030)

8.3.3 China Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Drugs for Central Nervous System Diseases Market Size (2019-2030)

9.2 Asia Drugs for Central Nervous System Diseases Market Size by Type

9.2.1 Asia Drugs for Central Nervous System Diseases Market Size by Type (2019-2024)

9.2.2 Asia Drugs for Central Nervous System Diseases Market Size by Type (2025-2030)

9.2.3 Asia Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

9.3 Asia Drugs for Central Nervous System Diseases Market Size by Application

9.3.1 Asia Drugs for Central Nervous System Diseases Market Size by Application (2019-2024)

9.3.2 Asia Drugs for Central Nervous System Diseases Market Size by Application (2025-2030)

9.3.3 Asia Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

9.4 Asia Drugs for Central Nervous System Diseases Market Size by Region

9.4.1 Asia Drugs for Central Nervous System Diseases Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Drugs for Central Nervous System Diseases Market Size by Region (2019-2024)

9.4.3 Asia Drugs for Central Nervous System Diseases Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Type

10.2.1 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Application

10.3.1 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Country

10.4.1 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Alkermes

11.1.1 Alkermes Company Details

11.1.2 Alkermes Business Overview

11.1.3 Alkermes Drugs for Central Nervous System Diseases Introduction

11.1.4 Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.1.5 Alkermes Recent Developments

11.2 Astrazeneca

11.2.1 Astrazeneca Company Details

11.2.2 Astrazeneca Business Overview

11.2.3 Astrazeneca Drugs for Central Nervous System Diseases Introduction

11.2.4 Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.2.5 Astrazeneca Recent Developments

11.3 Biogen

11.3.1 Biogen Company Details

11.3.2 Biogen Business Overview

11.3.3 Biogen Drugs for Central Nervous System Diseases Introduction

11.3.4 Biogen Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.3.5 Biogen Recent Developments

11.4 Bristol Myers Squibb

11.4.1 Bristol Myers Squibb Company Details

11.4.2 Bristol Myers Squibb Business Overview

11.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Introduction

11.4.4 Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.4.5 Bristol Myers Squibb Recent Developments

11.5 Lilly

11.5.1 Lilly Company Details

11.5.2 Lilly Business Overview

11.5.3 Lilly Drugs for Central Nervous System Diseases Introduction

11.5.4 Lilly Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.5.5 Lilly Recent Developments

11.6 GSK

11.6.1 GSK Company Details

11.6.2 GSK Business Overview

11.6.3 GSK Drugs for Central Nervous System Diseases Introduction

11.6.4 GSK Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.6.5 GSK Recent Developments

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Merck Business Overview

11.7.3 Merck Drugs for Central Nervous System Diseases Introduction

11.7.4 Merck Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.7.5 Merck Recent Developments

11.8 Sunovion Pharmaceuticals

11.8.1 Sunovion Pharmaceuticals Company Details

11.8.2 Sunovion Pharmaceuticals Business Overview

11.8.3 Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Introduction

11.8.4 Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.8.5 Sunovion Pharmaceuticals Recent Developments

11.9 Pfizer

11.9.1 Pfizer Company Details

11.9.2 Pfizer Business Overview

11.9.3 Pfizer Drugs for Central Nervous System Diseases Introduction

11.9.4 Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.9.5 Pfizer Recent Developments

11.10 Teva

11.10.1 Teva Company Details

11.10.2 Teva Business Overview

11.10.3 Teva Drugs for Central Nervous System Diseases Introduction

11.10.4 Teva Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.10.5 Teva Recent Developments

11.11 Norvatis

11.11.1 Norvatis Company Details

11.11.2 Norvatis Business Overview

11.11.3 Norvatis Drugs for Central Nervous System Diseases Introduction

11.11.4 Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)

11.11.5 Norvatis Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Alkermes plc

Astrazeneca plc

Biogen

Bristol–Myers Squibb

Lilly

GSK

Merck

Sunovion Pharmaceuticals

Pfizer Inc

TEVA

Norvatis

List of Tables

Table 1. Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Antidepressants

Table 3. Key Players of Anxiolytics

Table 4. Key Players of Anti-manic

Table 5. Key Players of Other

Table 6. Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 7. Global Drugs for Central Nervous System Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Drugs for Central Nervous System Diseases Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Drugs for Central Nervous System Diseases Market Share by Region (2019-2024)

Table 10. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Drugs for Central Nervous System Diseases Market Share by Region (2025-2030)

Table 12. Drugs for Central Nervous System Diseases Market Trends

Table 13. Drugs for Central Nervous System Diseases Market Drivers

Table 14. Drugs for Central Nervous System Diseases Market Challenges

Table 15. Drugs for Central Nervous System Diseases Market Restraints

Table 16. Global Drugs for Central Nervous System Diseases Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Drugs for Central Nervous System Diseases Revenue Share by Players (2019-2024)

Table 18. Global Top Drugs for Central Nervous System Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Central Nervous System Diseases as of 2023)

Table 19. Global Drugs for Central Nervous System Diseases Industry Ranking 2022 VS 2023 VS 2024

Table 20. Global 5 Largest Players Market Share by Drugs for Central Nervous System Diseases Revenue (CR5 and HHI) & (2019-2024)

Table 21. Global Key Players of Drugs for Central Nervous System Diseases, Headquarters and Area Served

Table 22. Global Key Players of Drugs for Central Nervous System Diseases, Product and Application

Table 23. Global Key Players of Drugs for Central Nervous System Diseases, Product and Application

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Drugs for Central Nervous System Diseases Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2019-2024)

Table 27. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2025-2030)

Table 29. Global Drugs for Central Nervous System Diseases Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Drugs for Central Nervous System Diseases Revenue Share by Application (2019-2024)

Table 31. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Drugs for Central Nervous System Diseases Revenue Share by Application (2025-2030)

Table 33. North America Drugs for Central Nervous System Diseases Market Size by Type (2019-2024) & (US$ Million)

Table 34. North America Drugs for Central Nervous System Diseases Market Size by Type (2025-2030) & (US$ Million)

Table 35. North America Drugs for Central Nervous System Diseases Market Size by Application (2019-2024) & (US$ Million)

Table 36. North America Drugs for Central Nervous System Diseases Market Size by Application (2025-2030) & (US$ Million)

Table 37. North America Drugs for Central Nervous System Diseases Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. North America Drugs for Central Nervous System Diseases Market Size by Country (2019-2024) & (US$ Million)

Table 39. North America Drugs for Central Nervous System Diseases Market Size by Country (2025-2030) & (US$ Million)

Table 40. Europe Drugs for Central Nervous System Diseases Market Size by Type (2019-2024) & (US$ Million)

Table 41. Europe Drugs for Central Nervous System Diseases Market Size by Type (2025-2030) & (US$ Million)

Table 42. Europe Drugs for Central Nervous System Diseases Market Size by Application (2019-2024) & (US$ Million)

Table 43. Europe Drugs for Central Nervous System Diseases Market Size by Application (2025-2030) & (US$ Million)

Table 44. Europe Drugs for Central Nervous System Diseases Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Europe Drugs for Central Nervous System Diseases Market Size by Country (2019-2024) & (US$ Million)

Table 46. Europe Drugs for Central Nervous System Diseases Market Size by Country (2025-2030) & (US$ Million)

Table 47. China Drugs for Central Nervous System Diseases Market Size by Type (2019-2024) & (US$ Million)

Table 48. China Drugs for Central Nervous System Diseases Market Size by Type (2025-2030) & (US$ Million)

Table 49. China Drugs for Central Nervous System Diseases Market Size by Application (2019-2024) & (US$ Million)

Table 50. China Drugs for Central Nervous System Diseases Market Size by Application (2025-2030) & (US$ Million)

Table 51. Asia Drugs for Central Nervous System Diseases Market Size by Type (2019-2024) & (US$ Million)

Table 52. Asia Drugs for Central Nervous System Diseases Market Size by Type (2025-2030) & (US$ Million)

Table 53. Asia Drugs for Central Nervous System Diseases Market Size by Application (2019-2024) & (US$ Million)

Table 54. Asia Drugs for Central Nervous System Diseases Market Size by Application (2025-2030) & (US$ Million)

Table 55. Asia Drugs for Central Nervous System Diseases Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 56. Asia Drugs for Central Nervous System Diseases Market Size by Region (2019-2024) & (US$ Million)

Table 57. Asia Drugs for Central Nervous System Diseases Market Size by Region (2025-2030) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Type (2019-2024) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Type (2025-2030) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Application (2019-2024) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Application (2025-2030) & (US$ Million)

Table 62. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 63. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Country (2019-2024) & (US$ Million)

Table 64. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size by Country (2025-2030) & (US$ Million)

Table 65. Alkermes Company Details

Table 66. Alkermes Business Overview

Table 67. Alkermes Drugs for Central Nervous System Diseases Product

Table 68. Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 69. Alkermes Recent Developments

Table 70. Astrazeneca Company Details

Table 71. Astrazeneca Business Overview

Table 72. Astrazeneca Drugs for Central Nervous System Diseases Product

Table 73. Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 74. Astrazeneca Recent Developments

Table 75. Biogen Company Details

Table 76. Biogen Business Overview

Table 77. Biogen Drugs for Central Nervous System Diseases Product

Table 78. Biogen Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 79. Biogen Recent Developments

Table 80. Bristol Myers Squibb Company Details

Table 81. Bristol Myers Squibb Business Overview

Table 82. Bristol Myers Squibb Drugs for Central Nervous System Diseases Product

Table 83. Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 84. Bristol Myers Squibb Recent Developments

Table 85. Lilly Company Details

Table 86. Lilly Business Overview

Table 87. Lilly Drugs for Central Nervous System Diseases Product

Table 88. Lilly Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 89. Lilly Recent Developments

Table 90. GSK Company Details

Table 91. GSK Business Overview

Table 92. GSK Drugs for Central Nervous System Diseases Product

Table 93. GSK Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 94. GSK Recent Developments

Table 95. Merck Company Details

Table 96. Merck Business Overview

Table 97. Merck Drugs for Central Nervous System Diseases Product

Table 98. Merck Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 99. Merck Recent Developments

Table 100. Sunovion Pharmaceuticals Company Details

Table 101. Sunovion Pharmaceuticals Business Overview

Table 102. Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Product

Table 103. Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 104. Sunovion Pharmaceuticals Recent Developments

Table 105. Pfizer Company Details

Table 106. Pfizer Business Overview

Table 107. Pfizer Drugs for Central Nervous System Diseases Product

Table 108. Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 109. Pfizer Recent Developments

Table 110. Teva Company Details

Table 111. Teva Business Overview

Table 112. Teva Drugs for Central Nervous System Diseases Product

Table 113. Teva Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 114. Teva Recent Developments

Table 115. Norvatis Company Details

Table 116. Norvatis Business Overview

Table 117. Norvatis Drugs for Central Nervous System Diseases Product

Table 118. Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)

Table 119. Norvatis Recent Developments

Table 120. Research Programs/Design for This Report

Table 121. Key Data Information from Secondary Sources

Table 122. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Drugs for Central Nervous System Diseases Market Share by Type: 2023 VS 2030

Figure 3. Antidepressants Features

Figure 4. Anxiolytics Features

Figure 5. Anti-manic Features

Figure 6. Other Features

Figure 7. Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 8. Global Drugs for Central Nervous System Diseases Market Share by Application: 2023 VS 2030

Figure 9. Hospital Pharmacies Case Studies

Figure 10. Retail Pharmacies Case Studies

Figure 11. Online Pharmacies Case Studies

Figure 12. Drugs for Central Nervous System Diseases Report Years Considered

Figure 13. Global Drugs for Central Nervous System Diseases Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Drugs for Central Nervous System Diseases Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Drugs for Central Nervous System Diseases Market Share by Region: 2023 VS 2030

Figure 16. Global Drugs for Central Nervous System Diseases Market Share by Players in 2023

Figure 17. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Central Nervous System Diseases as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Drugs for Central Nervous System Diseases Revenue in 2023

Figure 19. North America Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

Figure 21. North America Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

Figure 22. North America Drugs for Central Nervous System Diseases Market Share by Country (2019-2030)

Figure 23. United States Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Drugs for Central Nervous System Diseases Market Size YoY (2019-2030) & (US$ Million)

Figure 26. Europe Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

Figure 27. Europe Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

Figure 28. Europe Drugs for Central Nervous System Diseases Market Share by Country (2019-2030)

Figure 29. Germany Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. France Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. U.K. Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Italy Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Russia Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Nordic Countries Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. China Drugs for Central Nervous System Diseases Market Size YoY (2019-2030) & (US$ Million)

Figure 36. China Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

Figure 37. China Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

Figure 38. Asia Drugs for Central Nervous System Diseases Market Size YoY (2019-2030) & (US$ Million)

Figure 39. Asia Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

Figure 40. Asia Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

Figure 41. Asia Drugs for Central Nervous System Diseases Market Share by Region (2019-2030)

Figure 42. Japan Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. South Korea Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. China Taiwan Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. India Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Australia Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Size YoY (2019-2030) & (US$ Million)

Figure 49. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Share by Type (2019-2030)

Figure 50. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Share by Application (2019-2030)

Figure 51. Middle East, Africa, and Latin America Drugs for Central Nervous System Diseases Market Share by Country (2019-2030)

Figure 52. Brazil Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Mexico Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Turkey Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. Saudi Arabia Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Israel Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. GCC Countries Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 58. Alkermes Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 59. Astrazeneca Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 60. Biogen Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 61. Bristol Myers Squibb Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 62. Lilly Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 63. GSK Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 64. Merck Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 65. Sunovion Pharmaceuticals Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 66. Pfizer Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 67. Teva Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 68. Norvatis Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Central Nervous System Biomarkers Market Insights Forecast to 2030

Central Nervous System Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Central Nervous System Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Central Nervous System Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Central Nervous System Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Central Nervous System Disorders Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Neurodegenerative Disease Market Insights Forecast to 2030

Global Diabetic Neurological Disorder Therapeutic Drug Market Insights Forecast to 2030

Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030

Global Nervous System Chemicals Market Research Report 2024

Global Anti Parkinson Drugs Market Insights Forecast to 2030

Global Multiple Sclerosis Drugs Treatment Market Insights Forecast to 2030

Central Nervous System CNS Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Rheumatic Disorders Drug Market Insights Forecast to 2030

Global Digital Therapeutics for Nervous System Diseases Market Research Report 2024

Central Nervous System Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Neurodegenerative Diseases Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Leishmaniasis Treatment Market Insights Forecast to 2030

Global Neurodegenerative Disease Treatment Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions